Previous studies found that ASCT2 forms a heterotrimeric molecular complex with EGFR and AP1G1; thus, cetuximab could co-target ASCT2 via EGFR endocytosis and decrease intracellular glutamine levels in HNSCC.20,22 In contrast, the effect of ASCT2 targeting on the response of HNSCC to cetuximab remained unclear. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.